Name : Human ICOS/CD278 Protein
Product Source :
Recombinant Human ICOS/CD278 Protein is expressed from HEK293 with His tag at the C-Terminus. It contains Glu21-Gln134.[Accession | Q9Y6W8-1]
Molecular Weight :
The protein has a predicted MW of 14.6 kDa. Due to glycosylation, the protein migrates to 25-35 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 90% as determined by Tris-Bis PAGE> 90% as determined by HPLC
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt.-80°C for 3-6 months after reconstitution.2-8°C for 2-7 days after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Human ICOS on Tris-Bis PAGE under reduced condition. The purity is greater than 90%. SEC-HPLC The purity of Human ICOS is greater than 90% as determined by SEC-HPLC. ELISA Data Immobilized Human ICOS, His Tag at 0.5μg/ml (100μl/Well) on the plate. Dose response curve for Human B7-H2, hFc Tag with the EC50 of 25.3ng/ml determined by ELISA.
Background :
Inducible co-stimulator (ICOS), also called AILIM (activiation-inducible lymphocyte immunomediatory molecule) and CRP-1 (CD28-related protein-1), is a member of the growing CD28 family of immune costimulatory receptors. Other family members are CD28, CTLA-4 and PD-1. Human ICOS is a homodimeric type I transmembrane protein consisting of 199 amino acids (aa) with a putative 20 aa signal sequence, a 121 aa extracellular domain, a 23 aa transmembrane region, and a 35 aa cytoplasmic domain.
Synonyms :
AILIM; CD278; CRP-1; CVID1; ICOS; MGC39850
References & Citations :
(1) ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity. 2019
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
TNF-alpha/TNFSF2 Protein
BCL2 Protein
Popular categories:
Insulin Receptor (INSR)
Fc Receptor Like 2 (FCRL2)